SCHEDULE 13G: Vanguard Group Discloses 7.13% Passive Stake in CytoSorbents Corp

The Vanguard Group has reported a 7.13% passive beneficial ownership stake in CytoSorbents Corp's common stock as of December 31, 2024.

Summary

• The Vanguard Group filed a Schedule 13G with the SEC, disclosing its beneficial ownership of common stock in CytoSorbents Corp.
• As of December 31, 2024, Vanguard beneficially owns an aggregate of 3,899,102 shares of CytoSorbents Corp, which represents 7.13% of the company's common stock class.
• Vanguard holds sole dispositive power over 3,871,372 shares and shared dispositive power over 27,730 shares, but holds no sole or shared voting power over these securities.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of CytoSorbents Corp.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership, which is inherently neutral in sentiment. While institutional ownership can be seen as a positive signal, the filing itself does not contain performance or strategic information to influence sentiment.

Positives

• The disclosure of a significant 7.13% stake by The Vanguard Group, a major institutional investor, indicates a notable investment position in CytoSorbents Corp.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership in the company.
• Company Management: Indicates the presence of a large, passive institutional shareholder.

Key Dates

Keywords

CytoSorbents Corp, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment, SEC filing